Last reviewed · How we verify
Insulin Degludec U100 — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Insulin Degludec U100 (Insulin Degludec U100) — Weill Cornell Medical College in Qatar.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Insulin Degludec U100 TARGET | Insulin Degludec U100 | Weill Cornell Medical College in Qatar | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Insulin Degludec U100 CI watch — RSS
- Insulin Degludec U100 CI watch — Atom
- Insulin Degludec U100 CI watch — JSON
- Insulin Degludec U100 alone — RSS
Cite this brief
Drug Landscape (2026). Insulin Degludec U100 — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-degludec-u100. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab